Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?

Area of Science:

• Pharmacogenetics
• Drug Metabolism
• Clinical Pharmacology

Background:

• Codeine's analgesic and toxic effects depend on its conversion to morphine via CYP2D6 (cytochrome P450 2D6).
• Identifying individuals with very low or high morphine formation is crucial for optimizing codeine therapy efficacy and safety.

Purpose of the Study:

• To evaluate the performance of different CYP2D6 phenotyping and genotyping systems in predicting morphine formation from codeine.
• To assess the ability of these systems to identify patients likely to under-respond or experience toxicity from codeine.

Main Methods:

• A study involving 57 healthy Caucasians administered dextromethorphan and codeine.
• Comparison of traditional CYP2D6 genotype-based classification, a CYP2D6 activity score, and plasma dextromethorphan metabolic ratio for phenotyping.

Main Results:

• CYP2D6-based systems accurately identified 87.5% of individuals with low morphine formation (poor responders).
• Predicting high morphine formation (at risk for toxicity) was less accurate: genotyping identified 50% (gene duplication), while phenotyping identified 67.5%.
• Combining genotyping and phenotyping improved prediction of high morphine formation to 87.5%.

Conclusions:

• Current CYP2D6 phenotyping and genotyping effectively predict insufficient morphine formation, indicating likely codeine treatment failure.
• Accurate prediction of extremely high morphine formation, essential for codeine safety, requires a combined genotyping and phenotyping approach.